Author’s Reply to Perera et al.: A Commentary on “An Early Cost–Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom”
本文未提供摘要，请点击“查看全文”查看完整内容。